{"filing":{"accession_number":"0001372514-26-000075","cik":"0001372514","ticker":"KPHMW","company_name":"KIORA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"kprx-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/kprx-20260807.htm"},"events":[{"id":26174,"run_id":23772,"accession_number":"0001372514-26-000075","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and comprehensive loss. The Item 2.02 disclosure explicitly states \"On May 8, 2026, Kiora Pharmaceuticals, Inc. (the 'Company') issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress,\" with the full press release attached as Exhibit 99.1. The filing includes detailed financial tables and operating metrics typical of an earnings announcement.","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27203,"accession_number":"0001372514-26-000075","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and comprehensive loss. The Item 2.02 disclosure explicitly states \"On May 8, 2026, Kiora Pharmaceuticals, Inc. (the 'Company') issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress,\" with the full press release attached as Exhibit 99.1. The filing includes detailed financial tables and operating metrics typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:11:31.927778+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27203,"accession_number":"0001372514-26-000075","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and comprehensive loss. The Item 2.02 disclosure explicitly states \"On May 8, 2026, Kiora Pharmaceuticals, Inc. (the 'Company') issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress,\" with the full press release attached as Exhibit 99.1. The filing includes detailed financial tables and operating metrics typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:11:31.927778+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-08-07"}]}